Form 4: Integra LifeSciences Exec Reports Stock Transactions

Integra LifeSciences EVP Michael McBreen reported the acquisition of 92,108 restricted stock units and the disposition of 9,601 common shares for tax purposes.

Summary

• Michael J. McBreen, Executive Vice President and President of CSS at Integra LifeSciences Holdings Corp (IART), reported changes in his beneficial ownership.
• Disposed of 2,354 shares of common stock on March 10, 2026, at a price of $9.55 per share.
• Disposed of an additional 7,247 shares of common stock on March 11, 2026, at a price of $9.61 per share. These dispositions (Transaction Code 'F') are typically related to tax withholding upon the vesting of equity awards.
• Acquired 92,108 Restricted Stock Units (RSUs) on March 11, 2026, with a grant price of $0.
• The newly acquired RSUs will vest in a staggered manner: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the March 11, 2026 grant date.
• Following these transactions, McBreen directly beneficially owns 60,743 shares of common stock and 92,108 Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices and associated tax-related share dispositions, with no immediate positive or negative implications for company fundamentals or strategic direction.

Positives

• The acquisition of 92,108 Restricted Stock Units (RSUs) indicates continued equity incentive for a key executive, aligning management's interests with long-term shareholder value.

Negatives

• The disposition of 9,601 common shares, while likely for tax withholding, reduces the executive's direct common stock holdings.

Future Outlook

The Restricted Stock Units granted on March 11, 2026, are scheduled to vest in three tranches: 33% on March 11, 2027, 33% on March 11, 2028, and 34% on March 11, 2029.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, often related to executive compensation and tax planning, and do not typically reflect strategic shifts or operational performance. These transactions are standard practice within the industry for incentivizing and compensating senior management.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine compensation-related transactions. The RSU grant aligns executive incentives with long-term share price performance.
• Employees: No direct impact mentioned.

Next Steps

• First tranche of Restricted Stock Units (33%) will vest on March 11, 2027.
• Second tranche of Restricted Stock Units (33%) will vest on March 11, 2028.
• Third tranche of Restricted Stock Units (34%) will vest on March 11, 2029.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the grant of restricted stock units and the disposition of shares for tax withholding. Such transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell.

Keywords

Integra LifeSciences, IART, Form 4, insider transaction, restricted stock units, executive compensation, Michael McBreen